content: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date  of  Report  (Date  of earliest event reported)       MAY 20, 1996 
  
                                        ENZON, INC.
  
                    (Exact name  of  registrant  as  specified  in  its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  
  
  
  <PAGE>
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc.  ("Enzon"  or the "Company") completed its Phase  Ia
  clinical trial in healthy volunteers  at  the  end  of  1995,  and received
  approval  from  the  FDA  to  enter  a multi-dose trial in cancer patients.
  Enrollment of patients for this trial  has been unexpectedly slow, and as a
  result,  the  Company  has  just opened a second  site  and  plans  to  add
  additional sites.  The clinical  supplies for the trial have been delivered
  to  the  open sites.  To expedite completion  of  this  trial,  a  clinical
  research organization  will  be utilized to accelerate patient recruitment,
  monitor the study, and compile results.
  <PAGE>
  
  
  
                              SIGNATURES
  
  
       Pursuant to the requirements  of  the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  May 29, 1996
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 2310}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96573653"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date  of  Report  (Date  of earliest event reported)       MAY 20, 1996 
  
                                        ENZON, INC.
  
                    (Exact name  of  registrant  as  specified  in  its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc.  ("Enzon"  or the "Company") completed its Phase  Ia
  clinical trial in healthy volunteers  at  the  end  of  1995,  and received
  approval  from  the  FDA  to  enter  a multi-dose trial in cancer patients.
  Enrollment of patients for this trial  has been unexpectedly slow, and as a
  result,  the  Company  has  just opened a second  site  and  plans  to  add
  additional sites.  The clinical  supplies for the trial have been delivered
  to  the  open sites.  To expedite completion  of  this  trial,  a  clinical
  research organization  will  be utilized to accelerate patient recruitment,
  monitor the study, and compile results.
  SIGNATURES
  
       Pursuant to the requirements  of  the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  May 29, 1996
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer